查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1584135

神經內分泌腫瘤治療市場，按治療類型、藥物類別、腫瘤類型、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Neuroendocrine Tumor Treatment Market, By Therapy Type, By Drug Class, By Tumor Type, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年神經內分泌腫瘤治療市場規模為25.1021億美元，2024年至2032年年複合成長率為9.10%。

神經內分泌腫瘤治療市場-市場動態

越來越多的臨床試驗加速了神經內分泌腫瘤治療市場的創新

越來越多的臨床試驗顯著加速神經內分泌腫瘤（NET）治療市場的創新，反映出人們越來越重視開發標靶療法。例如，2021年，美國國立衛生研究院（NIH）報告了超過 350 項專門針對 NET 的活躍臨床試驗，凸顯了探索新治療途徑的緊迫性。Novartis和Ipsen等製藥公司在臨床研究上投入巨資，以評估新型藥物，包括生長抑素類似物和胜肽受體放射性核素療法（PRRT）。此外，歐洲神經內分泌腫瘤協會（ENETS）等計劃在促進合作研究工作、促進治療方案的更快進展方面發揮了重要作用。因此，這些努力預計將產生有前景的新療法，並提高神經內分泌腫瘤患者的治療效果和生活品質。

神經內分泌腫瘤治療市場-關鍵見解

根據研究分析師的分析，預計全球市場在預測期內（2024-2032）每年將以 9.10%左右的年複合成長率成長

根據治療類型細分，生長抑素模擬療法預計將在2023年顯示最大的市場佔有率

根據藥物類別細分，生長抑素類似物是2023年的主導類型

根據腫瘤類型細分，胃腸胰神經內分泌腫瘤（GEP-NETs）是2023年的主要類型

依地區分類，北美是2023年的主要收入來源

神經內分泌腫瘤治療市場-細分分析：

全球神經內分泌腫瘤治療市場根據治療類型、藥物類別、腫瘤類型、最終用戶和地區進行細分。

根據治療類型，市場分為四類：生長抑素類似療法、胜肽受體放射性核素治療（PRRT）、標靶治療和化療。生長抑素類似療法因其在症狀管理方面的既定功效而處於領先地位。緊隨其後的是胜肽受體放射性核素療法（PRRT），它獲得了標靶治療的牽引力。標靶治療和化療也很重要，儘管優先順序較低。

根據藥物類別，市場分為四類：生長抑素類似物、酪胺酸激酶抑制劑、mTOR 抑制劑和烷基化劑。生長抑素類似物因其在控制症狀和腫瘤生長方面的有效性而具有最高優先順序。隨後是酪胺酸激酶抑制劑，提供針對性的作用。 mTOR 抑制劑和烷基化劑也很重要，但優先順序較低。

神經內分泌腫瘤治療市場-地理洞察

神經內分泌腫瘤（NET）治療市場在盛行率、治療選擇和研究活動方面表現出顯著的地理差異。在先進的醫療基礎設施和對腫瘤學研究的大量投資的推動下，北美脫穎而出，成為領先地區，根據美國癌症協會的資料，美國每年報告約 12,000 例新的NET 病例。歐洲也發揮著非常重要的作用，特別是在德國和英國等國家，歐洲神經內分泌腫瘤協會（ENETS）等計劃促進研究人員和臨床醫生之間的合作，以加強治療方案和治療的可及性。在亞太地區，中國和印度等新興市場對神經內分泌腫瘤的認知和診斷率不斷提高，促使醫療保健提供者擴大治療選擇。此外，日本神經內分泌腫瘤學會等組織努力提高對 NET 的理解和管理，促進市場佔有率的成長。因此，這些地理見解顯示了一個動態的景觀，具有不同程度的治療進展和研究重點。

神經內分泌腫瘤治療市場-競爭格局：

神經內分泌腫瘤（NET）治療市場的競爭格局特徵是參與者多元化，包括製藥巨頭和專業生物技術公司。Novartis和Ipsen等領先機構處於領先地位，其藥物（包括Sandostatin和Somatuline在對症治療和腫瘤控制市場佔據主導地位。2023年，Novartis報告Sandostatin的銷售額超過20億美元，凸顯了其龐大的市場佔有率。 Advanced Accelerator Applications（Novartis子公司）和 Clovis Oncology 等新興企業創新療法方面取得長足進步，包括放射性配體治療和標靶治療，這些療法在臨床環境中越來越受到關注。合作和策略夥伴關係也很普遍，Bayer和Pfizer等公司尋求透過收購和合併來增強其產品組合，特別是Bayer收購了用於靶向放射性核素治療的鎦 Lu 177 的權利。此外，對研究和開發的關注仍然很高，大量臨床試驗探索新的治療方式，反映出目的是改善 NET 治療患者預後的充滿活力和競爭的環境。

最新進展：

2024年 1月，FDA 批准 Lu 177-dotatate（Lutathera）作為晚期神經內分泌腫瘤的初始治療藥物，與奧曲肽聯合使用可顯著改善無進展生存期和腫瘤縮小，增加了患者的治療選擇。

2024年 3月，FDA 授予 AlphaMedix（212Pb-DOTAMTATE）突破性療法認定，用於治療晚期胃腸胰腺神經內分泌腫瘤。這標誌著一項重大進步，因為它是第一個獲得這一地位的標靶阿爾法療法，加速了其發展。

目錄

第1章 神經內分泌腫瘤治療市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘錄
    • 依治療類型分類的神經內分泌腫瘤治療市場摘錄
    • 依藥物類別分類的神經內分泌腫瘤治療市場摘錄
    • 依腫瘤類型分類的神經內分泌腫瘤治療市場摘錄
    • 依最終使用者的神經內分泌腫瘤治療市場摘錄
    • 依國家/地區分類的神經內分泌腫瘤治療市場摘錄
    • 依地區分類的神經內分泌腫瘤治療市場摘錄
  • 競爭洞察

第3章 神經內分泌腫瘤治療主要市場趨勢

  • 神經內分泌腫瘤治療市場促進因素
    • 市場促進因素的影響分析
  • 神經內分泌腫瘤治療市場限制
    • 市場限制影響分析
  • 神經內分泌腫瘤治療市場機會
  • 神經內分泌腫瘤治療市場未來趨勢

第4章 神經內分泌腫瘤治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 神經內分泌腫瘤治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 神經內分泌腫瘤治療市場格局

  • 2023年神經內分泌腫瘤治療市佔分析
  • 依主要製造商分類的細分資料
    • 既有參與者分析
    • 新興參與者分析

第7章 神經內分泌腫瘤治療市場 - 依治療類型

  • 概述
    • 依治療類型分類的細分市場佔有率分析
    • 生長抑素類似療法
    • 胜肽受體放射性核種治療（PRRT）
    • 標靶治療
    • 化療

第8章 神經內分泌腫瘤治療市場 - 依藥物類別

  • 概述
    • 依藥物類別分類的細分市場佔有率分析
    • 生長抑素類似物
    • 酪胺酸激酶抑制劑
    • mTOR抑制劑
    • 烷基化劑

第9章 神經內分泌腫瘤治療市場 - 依腫瘤類型

  • 概述
    • 依腫瘤類型分類的細分市場佔有率分析
    • 胃腸胰神經內分泌腫瘤（GEP-NET）
    • 肺神經內分泌腫瘤
    • 其他

第10章 神經內分泌腫瘤治療市場 - 依最終用戶

  • 概述
    • 依最終用戶分類的細分市場佔有率分析
    • 醫院
    • 癌症專科診所
    • 研究所

第11章 神經內分泌腫瘤治療市場 - 依地理位置

  • 介紹
    • 依地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美神經內分泌腫瘤治療主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依治療類型）
    • 北美市場規模和預測（依藥物類別）
    • 北美市場規模和預測（依腫瘤類型）
    • 北美市場規模和預測（依最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲神經內分泌腫瘤治療主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模和預測（依治療類型）
    • 歐洲市場規模和預測（依藥物類別）
    • 歐洲市場規模和預測（依腫瘤類型）
    • 歐洲市場規模和預測（依最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區神經內分泌腫瘤治療主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模與預測（依治療類型）
    • 亞太地區市場規模和預測（依藥物類別）
    • 亞太地區市場規模與預測（依腫瘤類型）
    • 亞太地區市場規模和預測（依最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲神經內分泌腫瘤治療主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模與預測（依治療類型）
    • 拉丁美洲市場規模與預測（依藥物類別）
    • 拉丁美洲市場規模與預測（依腫瘤類型）
    • 拉丁美洲市場規模和預測（依最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲神經內分泌腫瘤治療主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模和預測（依治療類型）
    • 中東和非洲市場規模及預測（依藥物類別）
    • 中東和非洲市場規模及預測（依腫瘤類型）
    • 中東和非洲市場規模和預測（依最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA其他

第12章 主要供應商分析-神經內分泌腫瘤治療產業

  • 競爭儀表板
  • 公司簡介
    • Novartis AG
    • Pfizer Inc.
    • Ipsen SA
    • Advanced Accelerator Applications SA
    • Merck & Co., Inc.
    • AstraZeneca PLC
    • Roche Holding AG
    • Bristol-Myers Squibb Company
    • Bayer AG
    • GlaxoSmithKline plc
    • Eli Lilly and Company
    • Sanofi SA
    • Boehringer Ingelheim GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Hutchison China MediTech Limited（Hutchmed）
    • Lexicon Pharmaceuticals, Inc.
    • Others

第13章 360 度分析師視角

第14章 附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4115

REPORT HIGHLIGHT

Neuroendocrine Tumor Treatment Market size was valued at USD 2,510.21 Million in 2023, expanding at a CAGR of 9.10% from 2024 to 2032.

The Neuroendocrine Tumor Treatment Market focuses on therapies designed to manage neuroendocrine tumors (NETs), which originate from neuroendocrine cells and can occur in various organs. With an increasing global incidence of NETs-affecting approximately 6.98 cases per 100,000 people-the demand for effective treatment options is on the rise. Rising awareness about NETs, advancements in targeted therapies, and the growing number of clinical trials contribute significantly to market growth. However, high treatment costs and a lack of knowledge among healthcare professionals can hinder market expansion. Opportunities lie in the development of novel therapeutics and combination therapies, along with the potential for personalized medicine, which could enhance treatment efficacy. As healthcare systems evolve, the integration of advanced diagnostic techniques, such as PET scans and molecular imaging, is anticipated to improve patient outcomes and drive further growth in the market.

Neuroendocrine Tumor Treatment Market- Market Dynamics

Growing Number of Clinical Trials Accelerates Innovation in the Neuroendocrine Tumor Treatment Market

The growing number of clinical trials is significantly accelerating innovation in the neuroendocrine tumor (NET) treatment market, reflecting an increasing focus on developing targeted therapies. For instance, in 2021, the National Institutes of Health (NIH) reported over 350 active clinical trials specifically for NETs, highlighting the urgency to explore new treatment avenues. Pharmaceutical companies such as Novartis and Ipsen have invested heavily in clinical research to evaluate novel agents, including somatostatin analogs and peptide receptor radionuclide therapy (PRRT). Furthermore, initiatives like the European Neuroendocrine Tumor Society (ENETS) have been instrumental in promoting collaborative research efforts, enabling faster advancements in treatment protocols. As a result, these efforts are anticipated to yield promising new therapies that enhance patient outcomes and quality of life for those diagnosed with neuroendocrine tumors.

Neuroendocrine Tumor Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.10% over the forecast period (2024-2032)

Based on Therapy Type segmentation, Somatostatin Analog Therapy was predicted to show maximum market share in the year 2023

Based on Drug Class segmentation, Somatostatin Analogs was the leading type in 2023

Based on Tumor Type segmentation, Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) were the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Neuroendocrine Tumor Treatment Market- Segmentation Analysis:

The Global Neuroendocrine Tumor Treatment Market is segmented on the basis of Therapy Type, Drug Class, Tumor Type, End-User, and Region.

The market is divided into four categories based on Therapy Type: Somatostatin Analog Therapy, Peptide Receptor Radionuclide Therapy (PRRT), Targeted Therapy, and Chemotherapy. Somatostatin Analog Therapy leads due to its established efficacy in symptom management. Following closely is Peptide Receptor Radionuclide Therapy (PRRT), gaining traction for targeted treatment. Targeted Therapy and Chemotherapy are also important, albeit with lower priority.

The market is divided into four categories based on Drug Class: Somatostatin Analogs, Tyrosine Kinase Inhibitors, mTOR Inhibitors, and Alkylating Agents. Somatostatin Analogs hold the highest priority due to their effectiveness in managing symptoms and tumor growth. Tyrosine Kinase Inhibitors follow, offering targeted action. mTOR Inhibitors and Alkylating Agents are also significant but with lower priority.

Neuroendocrine Tumor Treatment Market- Geographical Insights

The neuroendocrine tumor (NET) treatment market exhibits significant geographical variations in prevalence, treatment options, and research activities. North America stands out as the leading region, driven by advanced healthcare infrastructure and substantial investment in oncology research, with the U.S. reporting approximately 12,000 new NET cases annually according to the American Cancer Society. Europe also plays a crucial role, particularly in countries like Germany and the UK, where initiatives like the European Neuroendocrine Tumor Society (ENETS) foster collaboration among researchers and clinicians to enhance treatment protocols and access to therapies. In Asia-Pacific, emerging markets such as China and India are witnessing increasing awareness and diagnosis rates of neuroendocrine tumors, prompting healthcare providers to expand treatment options. Additionally, initiatives like the Japanese Society of Neuroendocrine Tumors are working to improve the understanding and management of NETs, thereby contributing to a growing market presence. As a result, these geographical insights indicate a dynamic landscape with varying levels of treatment advancements and research emphasis.

Neuroendocrine Tumor Treatment Market- Competitive Landscape:

The competitive landscape of the neuroendocrine tumor (NET) treatment market is characterized by a diverse array of players, including pharmaceutical giants and specialized biotech companies. Leading organizations such as Novartis and Ipsen are at the forefront, with their drugs, including Sandostatin and Somatuline, dominating the market for symptomatic treatment and tumor control. In 2023, Novartis reported over $2 billion in sales for Sandostatin, underscoring its significant market share. Emerging players like Advanced Accelerator Applications (a Novartis subsidiary) and Clovis Oncology are making strides with innovative therapies, including radioligand treatments and targeted therapies, which are gaining traction in clinical settings. Collaborations and strategic partnerships are also prevalent, as companies like Bayer and Pfizer seek to enhance their product portfolios through acquisitions and mergers, notably Bayer's acquisition of the rights to Lutetium Lu 177 for targeted radionuclide therapy. Furthermore, the focus on research and development remains high, with numerous clinical trials exploring novel treatment modalities, reflecting a vibrant and competitive environment aimed at improving patient outcomes in NET treatment.

Recent Developments:

In January 2024, the FDA's approval of Lu 177-dotatate (Lutathera) as an initial treatment for advanced neuroendocrine tumors, showed significant improvements in progression-free survival and tumor shrinkage when combined with octreotide, enhancing therapeutic options for patients.

In March 2024, the FDA granted breakthrough therapy designation to AlphaMedix (212Pb-DOTAMTATE) for treating advanced gastroenteropancreatic neuroendocrine tumors. This marks a significant advancement as it is the first targeted alpha therapy to receive this status, expediting its development.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Novartis AG
  • Pfizer Inc.
  • Ipsen S.A.
  • Advanced Accelerator Applications S.A.
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Roche Holding AG
  • Bristol-Myers Squibb Company
  • Bayer AG
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Sanofi S.A.
  • Boehringer Ingelheim GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Hutchison China MediTech Limited (Hutchmed)
  • Lexicon Pharmaceuticals, Inc.
  • Others

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Somatostatin Analog Therapy
  • Peptide Receptor Radionuclide Therapy (PRRT)
  • Targeted Therapy
  • Chemotherapy

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Somatostatin Analogs
  • Tyrosine Kinase Inhibitors
  • mTOR Inhibitors
  • Alkylating Agents

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY TUMOR TYPE- MARKET ANALYSIS, 2019 - 2032

  • Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
  • Lung Neuroendocrine Tumors
  • Others

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Cancer Specialty Clinics
  • Research Institutes

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neuroendocrine Tumor Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neuroendocrine Tumor Treatment Market Snippet by Therapy Type
    • 2.1.2. Neuroendocrine Tumor Treatment Market Snippet by Drug Class
    • 2.1.3. Neuroendocrine Tumor Treatment Market Snippet by Tumor Type
    • 2.1.4. Neuroendocrine Tumor Treatment Market Snippet by End-User
    • 2.1.5. Neuroendocrine Tumor Treatment Market Snippet by Country
    • 2.1.6. Neuroendocrine Tumor Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Neuroendocrine Tumor Treatment Key Market Trends

  • 3.1. Neuroendocrine Tumor Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neuroendocrine Tumor Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neuroendocrine Tumor Treatment Market Opportunities
  • 3.4. Neuroendocrine Tumor Treatment Market Future Trends

4. Neuroendocrine Tumor Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neuroendocrine Tumor Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Neuroendocrine Tumor Treatment Market Landscape

  • 6.1. Neuroendocrine Tumor Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neuroendocrine Tumor Treatment Market - By Therapy Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
    • 7.1.2. Somatostatin Analog Therapy
    • 7.1.3. Peptide Receptor Radionuclide Therapy (PRRT)
    • 7.1.4. Targeted Therapy
    • 7.1.5. Chemotherapy

8. Neuroendocrine Tumor Treatment Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 8.1.2. Somatostatin Analogs
    • 8.1.3. Tyrosine Kinase Inhibitors
    • 8.1.4. mTOR Inhibitors
    • 8.1.5. Alkylating Agents

9. Neuroendocrine Tumor Treatment Market - By Tumor Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Tumor Type, 2023 & 2032 (%)
    • 9.1.2. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    • 9.1.3. Lung Neuroendocrine Tumors
    • 9.1.4. Others

10. Neuroendocrine Tumor Treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Cancer Specialty Clinics
    • 10.1.4. Research Institutes

11. Neuroendocrine Tumor Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Neuroendocrine Tumor Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Neuroendocrine Tumor Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Neuroendocrine Tumor Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Neuroendocrine Tumor Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Neuroendocrine Tumor Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Neuroendocrine Tumor Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Novartis AG
    • 12.2.2. Pfizer Inc.
    • 12.2.3. Ipsen S.A.
    • 12.2.4. Advanced Accelerator Applications S.A.
    • 12.2.5. Merck & Co., Inc.
    • 12.2.6. AstraZeneca PLC
    • 12.2.7. Roche Holding AG
    • 12.2.8. Bristol-Myers Squibb Company
    • 12.2.9. Bayer AG
    • 12.2.10. GlaxoSmithKline plc
    • 12.2.11. Eli Lilly and Company
    • 12.2.12. Sanofi S.A.
    • 12.2.13. Boehringer Ingelheim GmbH
    • 12.2.14. Teva Pharmaceutical Industries Ltd.
    • 12.2.15. Hutchison China MediTech Limited (Hutchmed)
    • 12.2.16. Lexicon Pharmaceuticals, Inc.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us